Ned Pojskic News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ned pojskic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ned Pojskic Today - Breaking & Trending Today
GreenShield has launched a first-of-its-kind program to provide essential medications to low income Canadians without public or private drug coverage. ....
Canadian medical cannabis companies look to benefits-covered patients for growth mjbizdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mjbizdaily.com Daily Mail and Mail on Sunday newspapers.
In Western Canada, specialty drugs’ share of private plans’ costs is 23%, due to pharmacare programs in three provinces automatically acting as first payer for prescription drugs after an income-based out of-pocket deductible, climbing to 38% in Atlantic Canada. As much as 60% of the current pipeline is focused on specialty medications, according to a 2020 report from Express Scripts Canada, with about 50% of drugs in the pipeline designed for oral administration, continuing a shift in costs from provincial to private plans. This framework is two-tiered, as a Green Shield Canada report notes each insurer places eligible high-cost drug claims from their fully-insured plans into their proprietary extended health-policy protection plan pools. The pooling threshold, typically upwards of $10,000, is negotiated between plan sponsor and carrier. ....
for those of you looking to catch-up on biosimilars in 2020 and what these experts are most excited about for the year(s) ahead. As the Editorial Board explores which challenges are ahead for 2021, it’s reassuring to note that sustainability is increasingly entering the U.S. biosimilars conversation. As you’ll note in this installment, there are several particularly passionate calls-to-action for companies to confront misinformation, collaborate with stakeholders, and to refine their commercial business models in the name of greater market efficiency. Though there is a lot to be done, it’s clear from these answers that stakeholders are relying more heavily on biosimilars and that it’s more important than ever for biosimilar companies to keep carrying the torch for more competition, cost-savings, value, and responsible pricing. ....